Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
-
– Initiated two Phase 3 clinical studies to evaluate tab-cel™ (tabelecleucel) in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed...
-
Launches Search for Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy...
-
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
-
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
-
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
-
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
-
– Three clinical sites for both the MATCH and ALLELE pivotal studies now open for enrollment in the U.S. – SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc....
-
– Pivotal studies to commence imminently – – Primary endpoint results and EU conditional marketing authorization submission expected in the first half of 2019 – – Company to host conference call and...
-
– Company to announce FDA clearance to initiate two Phase 3 tabelecleucel clinical studies – SOUTH SAN FRANCISCO, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc....